US stocks are mixed as Technology leads and Consumer Staples lags
- S&P 5000.0%
- Nasdaq 100+0.6%
- Dow-0.6%
- Russell 2000-0.6%
Per CNBC, Nasdaq rises as Anthropic is indicated to surge in its debut, lifting tech names.
Per CNBC, Nasdaq rises as Anthropic is indicated to surge in its debut, lifting tech names.
Per CNBC, the Dow fell more than 500 points as Nvidia sold off after earnings, with the S&P 500 down for a fifth day.
Per CNBC, the Dow fell as the Nvidia earnings bounce faded, while Investor's Business Daily notes Fed official Waller calling for a larger rate hike.
Per CNBC, the Dow dropped more than 800 points as the S&P 500 posted its lowest close since July, with Nasdaq sliding as Nvidia dragged down the AI trade.
Per CNBC, the Dow fell 400 points weighed by Home Depot and the Nasdaq slid ahead of Nvidia earnings.
Per CNBC, the Nasdaq fell more than 2% as Nvidia dragged down the AI trade, extending its slide to a third day.
Nvidia's leadership in AI names weighed on stocks, per CNBC, with investors awaiting its first earnings without Jensen Huang.
Per CNBC, the Nasdaq fell as Nvidia sold off, though the index notched its best week since August.
Hot PPI data (6.5% per Kalshi) and Fed's Goolsbee saying inflation is broad-based weigh on sentiment, per Wall St. Engine on X.
Per CNBC, stock futures declined as Jensen Huang's ouster sent Nvidia reeling and oil prices rose.
A monthly check looks reliable until you ask which markets it has actually survived. Two young income ETFs and a 2003 veteran reveal what a payment history hides, and the answer may…
Morgan Stanley quietly rebuilt itself from a trading house into a wealth machine, and income investors who stuck around have been paid handsomely. So why has the stock itself been so painful…
One molecule turned a diversified drugmaker into a trillion-dollar giant, yet recent buyers have watched shares swing hard even as revenue surged. Does Lilly's next chapter justify today's price, or has the…
Three funds, one brokerage account, and a monthly check big enough to live on. But one of the three quietly writes more than half the income, and its latest earnings fell short…
Artificial intelligence has become one of the biggest investment stories in generations. Trillions of dollars are flowing into data centers, advanced semiconductors, and the power infrastructure needed to support them. Investors have…
Your S&P 500 index fund buys everything, expensive or not. One lesser-known ETF filters the index down to 75 stocks, and its top holdings look nothing like the mega-cap names you expect.…
Fed minutes revealed a hawkish bloc bigger than the October vote let on, and Governor Waller says the central bank may need to shock people. Long bond holders now face a fork…
Anthropic begins trading on the Nasdaq today after pricing its IPO above the marketed range, and that one deal is reviving the battered AI trade before the market opens. The Nasdaq-100 tracker…
Nvidia's founder just walked out, and two retirees with identical 401(k) balances face wildly different risk. The fix costs nothing in taxes, but one tempting panic move could trigger a cascade of…
GTA VI just lit up Take-Two's stock, but the bigger story sits inside your retirement account. Three kinds of funds hold the stock, and they feel this launch very differently, so check…
Nucor beat the S&P 500 at every horizon, yet the stock sat near its 52-week low just a year ago. Here is what separates a patient steel holder from one forced to…
One lesser-known ETF was built to profit when your retirement portfolio bleeds, yet it has wiped out nearly all of its value over time. Before you treat it as crash insurance, find…
While the S&P 500 stumbled through a fourth straight loss, one megacap barely flinched and left its six peers far behind. Its premium price, a memory cost squeeze, and a Fed minutes…
A hedge fund can trim Microsoft the moment its view shifts. If you own it through a 401(k), an IRA, and a brokerage account, you may hold far more of the stock…
Prolia and XGEVA are collapsing under biosimilar pressure, yet Amgen keeps lifting its guidance. Which newer drugs are filling the gap, and what could still derail a stock trading near a 52-week…